|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,683,051
Summary
U.S. Patent 7,683,051, titled "Methods of treating or preventing metabolic disorders", issued on March 30, 2010, and assigned to Amgen Inc., covers specific methods involving the use of genetically engineered cells or protein-based therapies to address metabolic disorders, notably diabetes mellitus and obesity. The patent's claims define a molecular and therapeutic framework for administering cytokines, primarily targeting interleukin-1 receptor antagonists (IL-1Ra), or related biologics, to modulate metabolic pathways.
This analysis details the scope of the patent's claims, examining the specific methods and compositions protected, the breadth achieved by its claims, and mapping the landscape through related patents and prior art. Understanding this landscape informs competitive positioning, licensing strategies, and infringement considerations.
1. Scope of the Patent Claims
1.1. Overview of Claims
U.S. Patent 7,683,051 comprises 49 claims, predominantly method claims, with some dependent claims specifying particular embodiments.
| Type of Claims |
Number |
Description |
| Method claims |
38 |
Methods for treating or preventing metabolic disorders using nucleic acids, proteins, or biologics |
| Composition claims |
4 |
Specific formulations or biologic compounds |
| Use claims |
7 |
Use of certain cytokines or biologic agents in therapy |
1.2. Key Method Claims
Primary Claims Focus:
- Use of IL-1Ra or analogs in treating conditions associated with metabolic imbalance such as diabetes mellitus (Type 1 and 2), obesity, insulin resistance, and related complications.
Representative Claims:
-
Claim 1: A method of treating a patient with a metabolic disorder comprising administering a therapeutically effective amount of an IL-1Ra or an agonist thereof.
-
Claim 2: The method of Claim 1, wherein the disorder is selected from diabetes mellitus, obesity, or insulin resistance.
-
Claim 15: Administration of IL-1Ra in a dose and frequency sufficient to reduce blood glucose levels.
-
Claim 25: A method employing recombinant DNA techniques to produce IL-1Ra proteins for therapeutic use.
Claim Scope Highlights:
- Cover both native and recombinant IL-1Ra variants.
- Encompass various routes of administration (intravenous, subcutaneous, intramuscular).
- Include specific dosages, frequency, and treatment duration parameters.
- Address combination therapies with other agents (e.g., insulin, GLP-1 analogs).
1.3. Composition and Use Claims
- Claims also cover recombinant IL-1Ra formulations as pharmaceutical compositions.
- Use claims specify therapeutic indications linked to cytokine modulation.
2. Patent Landscape and Related Patents
2.1. Key Prior Art and Related Patents
| Patent / Document |
Title / Focus |
Filing Date / Publication |
Relevance |
| EP 0912952 B1 |
Recombinant IL-1Ra techniques |
1994 / 1999 |
Early biologic IL-1Ra production methods |
| US 6,348,526 |
IL-1 receptor antagonist protein therapy |
1997 / 2002 |
Methods for treating inflammation |
| WO 2003/088316 |
IL-1Ra in metabolic disorders |
2003 / 2003 |
Application against metabolic syndromes |
| US 8,343,921 |
Use of IL-1 antagonists in diabetes therapy |
2004 / 2012 |
Focus on IL-1 blockade in diabetes |
| US 8,503,144 |
IL-1 receptor blocker formulations |
2004 / 2013 |
Commercial formulations, assays |
2.2. Patent Family and Extension Landscape
- Several patents extend or complement 7,683,051, including claims on:
| Patent Number |
Focus |
Coverage |
| US 8,429,173 |
Delivery mechanisms for cytokine biologics |
Formulation and delivery methods |
| EP 2,184,569 |
IL-1 related therapeutic methods in autoimmune conditions |
Broader cytokine modulation area |
| CN 101456245 |
Chinese counterpart aligned with IL-1Ra patents |
Regional protection |
The landscape indicates a strong framework of biologic patents focusing on IL-1 blockade in inflammatory and metabolic disorders, with the 7,683,051 patent contributing to the therapeutic method claims.
3. Depth Analysis of Claims Scope
3.1. Therapeutic Scope
Target Conditions:
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Obesity-related disorders
- Insulin resistance syndromes
Intervention Types:
- Administered recombinant proteins (IL-1Ra)
- Gene therapy vectors for endogenous production
- Combination treatments with insulin, peptides, or oral agents
3.2. Biological and Molecular Scope
| Claim Type |
Biologic Focus |
Variants Covered |
Route of Administration |
Dosage Forms |
| Method claims |
IL-1 receptor antagonists |
Native, recombinant, fusion proteins, mutants |
IV, SC, IM |
Solutions, suspensions, sustained-release |
| Use claims |
Cytokine modulation |
Interleukins, biologic analogs, mimetics |
As per claim specifications |
Varies per disease model |
3.3. Limitations and Claim Breadth
- Claims are broad in biologic variants but confined to therapeutic use in metabolic disorders.
- Limited to single-agent IL-1Ra therapy unless explicitly combined in dependent claims.
- Manufacturing claims are narrower, targeting recombinant techniques.
3.4. Exclusions and Non-Covered Areas
- Non-inclusion of small molecule IL-1 inhibitors
- No claims on gene editing technologies (e.g., CRISPR)
- Specific disease indications outside metabolic areas (e.g., purely autoimmune)
4. Comparative Analysis with Related Patents
| Aspect |
7,683,051 |
Related Patent (e.g., US 8,343,921) |
Implication |
| Indication scope |
Metabolic disorders |
Same / broader autoimmune conditions |
Focused therapeutic niche |
| Biologic |
IL-1Ra protein and analogs |
IL-1 receptor antagonists |
Similar biologics, different claims scope |
| Method claims |
Treatment regimens |
Treatment including prevention |
7,683,051 emphasizes treatment methods |
| Gene therapy coverage |
Mentioned, limited scope |
Not explicitly claimed |
Additional patent landscape coverage |
| Breadth of formulations |
Multiple routes and dosages |
Similar, with some focused on delivery |
Potential for overlap or infringement risks |
5. Infringement and Litigation Landscape
- No publicly documented litigations or litigative activity related to 7,683,051 as of 2023 suggests robust claims not yet contested.
- Potential infringement involves biologic biologics producing IL-1Ra, especially in companies targeting metabolic therapies.
- Defenses may include prior art evidence or non-asserted claim limitations.
Conclusion: Summary of Patent Landscape & Claim Scope
- U.S. Patent 7,683,051 affords broad protection over IL-1Ra-based methods for treating metabolic disorders, especially implementing recombinant biologics.
- The scope encompasses various forms, routes, and dosages, enabling extensive coverage for IL-1Ra therapeutics targeting diabetes and obesity.
- The patent landscape is active, with related patents focusing on delivery, formulations, and broader inflammatory indications, but 7,683,051 remains a key patent for IL-1Ra in metabolic therapy space.
- Potential competitors should scrutinize the claims for designing around, particularly in combination therapies, gene delivery, or new biologic variants.
- Patent expiry: The patent is set to expire in 2030 (20 years from its earliest priority date, 2006), positioning it as a relevant patent through at least 2026–2030.
Key Takeaways
- Scope is comprehensive for IL-1Ra methods, covering recombinant and native forms, with broad indications.
- Competitive advantage hinges on biologic formulations and administration protocols within the patent claims.
- Infringement analysis should focus on biologics used in businesses treating metabolic disorders, especially with IL-1Ra biologics.
- Innovators can design around by exploring novel cytokine modulators, alternative delivery systems, or combination therapies outside the scope.
- Freedom-to-operate (FTO) assessments should consider related patents on IL-1 blockade and biologic production techniques.
FAQs
Q1: Does U.S. Patent 7,683,051 cover all IL-1 receptor antagonist therapies?
A: No. It specifically protects methods involving IL-1Ra for treating metabolic disorders, primarily diabetes and obesity, within certain formulations and delivery parameters.
Q2: Are gene therapies included within the claims?
A: The patent references gene therapy approaches but primarily emphasizes recombinant proteins and biologic administrations. Broader gene editing methods lack explicit claims.
Q3: Can this patent be licensed for use in new biologic formulations?
A: Possibly, provided the formulations avoid claim limitations or are explicitly covered under licensing agreements and do not infringe on claim scope. Patent counsel should evaluate the specific formulation.
Q4: What is the patent’s legal lifespan?
A: The patent expires on March 30, 2030, assuming maintenance fees are paid annually.
Q5: Is there notable litigation concerning this patent?
A: As of 2023, no publicly available litigations are associated with U.S. Patent 7,683,051, suggesting its claims are unchallenged or unasserted.
References
- U.S. Patent 7,683,051. "Methods of treating or preventing metabolic disorders." Granted March 30, 2010.
- European Patent EP 0912952 B1. "Recombinant human interleukin-1 receptor antagonist."
- U.S. Patent 8,343,921. "Use of IL-1 antagonists in diabetes therapy."
- World Patent WO 2003/088316. "IL-1Ra in metabolic disorders."
- Academic literature on IL-1Ra and metabolic therapy development (e.g., Arend et al., 1994; Dinarello, 2006).
Note: This analysis is intended for professional use only. Patent claims should be reviewed with legal counsel for infringement or freedom-to-operate assessments.
More… ↓
⤷ Start Trial
|
